Coya Therapeutics, Inc. ( (COYA) ) has released its Q4 earnings. Here is a breakdown of the information Coya Therapeutics, Inc. presented to its investors.
Coya Therapeutics, Inc., based in Houston, TX, is a clinical-stage biotechnology company focused on developing treatments that enhance regulatory T cell function to address systemic and neuroinflammation, targeting diseases such as Alzheimer’s, ALS, and Parkinson’s. In its fiscal 2024 financial results, Coya reported significant progress in its clinical trials, including positive outcomes from studies on Alzheimer’s and Frontotemporal Dementia, as well as alignment with the FDA on a planned Phase 2b trial for ALS. Financially, the company raised $10 million through a private placement and received strategic investments to support its development programs. Despite a net loss of $14.9 million in 2024, compared to $8.0 million in 2023, Coya’s cash position improved to $38.3 million, bolstered by financing activities. Looking ahead, Coya’s management remains optimistic about achieving key milestones in 2025, including the initiation of a Phase 2b trial for COYA 302 in ALS, supported by a strong scientific rationale and a robust pipeline.